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OP6
STIGMATIZATION IN DERMATOLOGY - AN 
OVERVIEW
Jacek Szepietowski1, Dimitre Dimitrov2 
1Department of Dermatology, Venereology and Allergology, Uni-
versity of Medicine, Wroclaw, Poland, and 2PMW Al Mafraq and 
Sheikh Khalifa Medical City, Abu Dhabi, UAE
Numerous medical conditions are recognized as stigmatizing 
their sufferers and certain skin diseases are among them. The 
visible lesions might become reason for stigmatization with 
consequent psychological stress and social withdrawal We ai-
med to analyze dermatological conditions where stigmatization 
process has been studied. We performed search on PubMed until 
November 2016 and found a huge number of articles (n = 548). 
After selection 58 articles remains, describing 20 dermatological 
conditions. Our research found that psoriasis is the most common 
skin disease, where the stigmatization experience was studied. 
Out of 58 articles, 18 dialed with stigmatization in psoriatic 
patients. Vitiligo, acne, leprosy, atopic dermatitis was among 
others skin conditions where stigmatization was studied. We 
found that stigmatization is a common and important problem. 
Visibility of skin lesions as well as cultural factors are the main 
ones contributing to the feeling of stigmatization. Different 
instruments were used to evaluate stigmatization by different 
research groups which limit the possibility to make a direct com-
parison between the studies. There is a need for more research 
in the field of stigmatization in dermatological conditions and 
an urgent need for creation special anti-stigmatization program/
programs for patients suffering from dermatoses.
OP7
APPEARANCE COMPARISONS AS MEDIATOR 
AND RISK FACTOR FOR ACNE-RELATED 
STIGMA
Kate Adkins1, Andrew Thompson1, Paul Overton1, Julia Moses2 
1Department of Psychology, and 2Department of History, Univer-
sity of Sheffield, Sheffield, UK
The present study was conducted to examine the relationship 
between Facebook use and internalised acne-stigmatisation, 
and to test whether appearance comparisons mediated this 
relationship. UK adults (n = 650) with acne symptoms comple-
ted online measures of Facebook use, Facebook photo-related 
activity, self-compassion, upwards/downwards skin-appearance 
comparisons (UPACS/DACS), and an adapted version of the 
Feelings of Stigmatisation Questionnaire. Multiple regression 
and bootstrapped moderated-mediation analyses were conducted 
to test the relationships between Facebook use and stigmatisa-
tion. Within Facebook users (91.1%), levels of photo-related 
activity positively correlated with upwards appearance compa-
risons r(592) = 0.17, p < 0.001, and stigmatisation r(592) = 0.14, 
p = 0.001. Photo-related activity no longer predicted stigmati-
sation when UPACS was added into the regression. Severity, 
UPACS score, DACS score and self-compassion accounted for 
42% of the variance in stigmatisation. UPACS score and self-
compassion accounted for the greatest change in R2 – 24% and 
5.4%, respectively. Mediation analysis indicated that there was 
a significant indirect effect of Facebook photo use on stigmati-
sation via upwards appearance comparison. The results suggest 
that upwards appearance comparisons mediated the relationship 
between Facebook photo-activity and acne-stigmatisation. Social 
media use should be considered when working with individuals 
with acne-related distress, with particular attention to the role of 
appearance comparisons. Self-compassion provides an additional 
avenue for reducing stigmatisation.
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MEASURING THE IMPACT OF 
DERMATOLOGICAL CONDITIONS ON 
FAMILY AND CAREGIVERS: A REVIEW OF 
DERMATOLOGY-SPECIFIC INSTRUMENTS 
Francesca Sampogna1, Andrew Finlay2, Sam Salek3, Pavel Cher-
nyshov4, Florence Dalgard5, Andrea Evers6, Dennis Linder7, 
Liana Manolache8, Servando Marron9, Françoise Poot10, Saskia 
Spillekom-van Koulil11, Åke Svensson5, Jacek Szepietowski12, Lucia 
Tomas-Aragones13, Damiano Abeni1
1Clinical Epidemiology Unit, Istituto Dermopatico Dell’immacolata 
(IDI) IRCCS FLMM, Rome, Italy, 2Division of Infection and Im-
munity, Department of Dermatology and Wound Healing, Cardiff 
University, Cardiff, UK, 3Department of Pharmacy, Pharmacology 
and Postgraduate Medicine, School of Life & Medical Sciences, 
University of Hertfordshire, Hatfield, UK, 4Department of Der-
matology and Venereology, National Medical University, Kiev, 
Ukraine, 5Department of Dermatology and Venereology, Skåne 
University Hospital, Lund University, Malmö, Sweden, 6Health, 
Medical, and Neuropsychology unit, Leiden University, Leiden, 
The Netherlands, 7Oslo Centre for Biostatistics and Epidemiology, 
University of Oslo, Oslo, Norway, 8Dali Medical, Dermatology, 
Bucharest, Romania, 9Department of Dermatology, Alcañiz Hospi-
tal, Aragon Health Sciences Institute, Zaragoza, Spain, 10Depart-
ment of Dermatology, ULB Erasme Hospital, Brussels, Belgium, 
11Department of Medical Psychology, Radboud University Medical 
Center, Nijmegen, the Netherlands, 12Department of Dermatology, 
Wroclaw Medical University, Wroclaw, Poland, and 14Department 
of Psychology, Aragon Health Sciences Institute, University of Za-
ragoza, Zaragoza, Spain
The patient is the centre of a web of relationships and the impact 
of his/her disease on family members and caregivers must be taken 
into account. The aim of this study was to identify the specific 
instruments that measure the impact of a dermatological disease 
on the quality of life (QoL) of family members, by performing a 
systematic search of the literature. Fifteen papers were identified, 
describing the creation and validation of nine instruments. Four 
of them concerned atopic dermatitis (Dermatitis Family Index, 
DFI; Parents’ Index QoL Atopic Dermatitis, PiQoL-AD; QoL in 
Primary Caregivers of children with Atopic Dermatitis, QPCAD; 
Childhood Atopic Dermatits Impact Scale, CADIS), two measu-
red the impact of psoriasis in family members (Psoriasis Family 
Index, PFI; FamilyPso), one the impact of epidermolysis bullosa 
(Epidermolysis Bullosa Burden of Disease, EB-BoD), one of 
ichthyosis (Family Burden Ichthyosis, FBI), and one was generic 
for dermatological conditions (Family Dermatology Life Quality 
Index, FDLQI). The EADV quality of life taskforce recommends 
that the impact of a skin disease on family and caregivers should 
be measured as part of any thorough evaluation of the burden of 
a disease. 
OP9
IS COPING OF ATOPIC DERMATITIS PATIENTS 
ORIGINATED FROM THEIR OWN CHARACTER 
OR SECONDARILY REMODELED BY DISEASE 
SUFFERING? OBVIOUS IMPROVEMENT OF 
COPING AND PSYCHIATRIC SYMPTOMS AFTER 
“TIGHT ECZEMA CONTROL”
Yoko Kataoka1, Sonomi Nakajima2
1Osaka Habikino Medical Center, Osaka, and 2Kobe Pharma. Uni-
viversity, Kobe, Japan
Objectives: Atopic dermatitis (AD) is well known to require 
stress management including coping strategies. However different 
